Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shoreline Biosciences
Biotech
Editas finds buyer for iNK programs 10 days after pipeline cull
Just 10 days after Editas dropped its iNK programs as part of a major restructuring, Shoreline Biosciences has snapped up the cell technology.
James Waldron
Jan 19, 2023 9:45am
Camp4 taps former Translate CMO for same role—Chutes & Ladders
Mar 18, 2022 9:30am
Gilead-backed Shoreline hires Pfizer's cancer vax science chief
Mar 15, 2022 10:15am
Gilead's Kite, Shoreline ink CAR-NK deal potentially worth $2.3B
Jun 18, 2021 8:55am
